Scinai Immunotherapeutics Ltd banner

Intrinsic Value

Not Available for SCNI

There is not enough data to reliably calculate the intrinsic value for Scinai Immunotherapeutics Ltd.

Do our valuations actually work? See backtest results .

Alternatives to SCNI

Fundamental Analysis

What Scinai Immunotherapeutics Does

Biotechnology Health Care

Scinai Immunotherapeutics Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The firm's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies.

Headquarters
Israel IL
Employees
45
IPO date
Jun 7, 2007
Read the full company overview
View Company Overview
Financials
Efficiency

Earnings Waterfall
Scinai Immunotherapeutics Ltd

Wall St Price Targets

Capital Returns

Competitive Landscape